"In answering FDA's request of last week to voluntarily remove Bextra (valdecoxib) from the market, pharmaceutical giant Pfizer efficiently set in motion the requisite actions, all the while disagreeing with FDA's conclusions about the prescription anti-inflammatory drug.
'Pfizer has not yet decided to recall, but rather has agreed to suspend marketing,' according to a Food & Drug Administration spokesperson. FDA defines recall as the 'removal or correction of a product actually in the distribution chain.'" [FrontLineToday.com]
